On February 6, 2013, field agents from the Denver, Colorado, office U.S. Drug Enforcement Administration inspected the site, safe, and alarm system that will protect the approximately eight grams of MDMA needed for our upcoming Boulder study of MDMA-assisted psychotherapy for PTSD. The agents’ report will be sent to DEA national headquarters, which will then review the report and decide whether to issue the Schedule I license to the study physician. Once the physician has received the license and the study drug, the site will begin recruiting and enrolling subjects.